Analyst Mitchell Kapoor from H.C. Wainwright reiterated a Buy rating on Legend Biotech (LEGN – Research Report) and keeping the price ...

Kostas Biliouris’s rating is based on several compelling factors that highlight Legend Biotech’s strong market position and future potential. The increasing uptake of Carvykti, driven by its ...

CARVYKTI demonstrated a 45% reduction in the risk of death compared to standard therapies in multiple myeloma patients.

It's another demonstration of Legend's commitment to expediting delivery of CARVYKTI to all patients who can benefit from it ...

Newly created position to lead efforts focused on continued growth and salesSOMERSET, N.J., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global ...

Legend Biotech has established itself as a key player in the multiple myeloma (MM) treatment space, primarily due to the success of Carvykti. This chimeric antigen receptor T-cell (CAR-T ...

Legend Biotech Corp (NASDAQ:LEGN), a biopharmaceutical company specializing in novel cell therapies for oncology, has been making waves in the healthcare sector with its flagship product, Carvykti. As ...

Arcellx has shared several data cuts on anito-cel, a CAR-T being developed with Gilead’s Kite Pharma to treat relapsed or ...

SOMERSET, N.J. - Legend Biotech Corporation (NASDAQ: LEGN), a global biotechnology company specializing in cell therapy, announced Monday the appointment of Alan Bash as the President of CARVYKTI ...

In this newly created role, Mr. Bash will be responsible for managing the continued growth of CARVYKTI®, overseeing Legend Biotech's commercial, technical operations, and quality functions of the ...

SOMERSET, N.J. - Legend Biotech Corporation (NASDAQ: LEGN), a global biotechnology company specializing in cell therapy, announced Monday the appointment of Alan Bash as the President of CARVYKTI, a ...